Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma
出版年份 2015 全文链接
标题
Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 15, Issue 9, Pages 981-993
出版商
Informa UK Limited
发表日期
2015-10-29
DOI
10.1586/14737140.2015.1074862
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- (2015) Daniel Sanghoon Shin et al. CURRENT OPINION IN IMMUNOLOGY
- Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
- (2015) A. Scholtens et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab: targeting PD-1 to bolster antitumor immunity
- (2015) Julie R Brahmer et al. Future Oncology
- A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
- (2015) Reinhard Dummer et al. Journal of Translational Medicine
- Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
- (2015) Georgina V Long et al. Journal of Translational Medicine
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
- (2015) D. B. Johnson et al. Cancer Immunology Research
- Nivolumab in melanoma: latest evidence and clinical potential
- (2015) Douglas B. Johnson et al. Therapeutic Advances in Medical Oncology
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential
- (2014) Morganna Freeman-Keller et al. Therapeutic Advances in Medical Oncology
- thanks to referees 2013
- (2013) ANNALS OF ONCOLOGY
- Emerging insights into resistance to BRAF inhibitors in melanoma
- (2013) Amanda D. Bucheit et al. BIOCHEMICAL PHARMACOLOGY
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
- (2013) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutaneous melanoma
- (2013) Alexander MM Eggermont et al. LANCET
- Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma
- (2013) Fatemeh Teimouri et al. MELANOMA RESEARCH
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of the PD-1 Pathway in the Immune Response
- (2012) L. V. Riella et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors
- (2012) Faruk Tas Journal of Oncology
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase Itch
- (2010) Holger Hoff et al. MOLECULAR IMMUNOLOGY
- Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline
- (2009) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started